Cancer research moves fast. We make it understandable.
In the single-arm Study ASTX727-07, an all-oral combination of decitabine/cedazuridine (Inqovi) plus venetoclax produced a complete remission rate of 41.6% (and a combined complete-remission-or-partial-hematologic-recovery rate of 52.5%) in older or…
Primary source cited
Last reviewed
In experimental/preclinical models, a tardigrade-protein-inspired, nanoparticle-delivered mRNA strategy reduced radiation-induced DNA damage in oral and rectal tissue.
Primary source cited
Last reviewed
In a large randomized trial (105,934 participants), AI-supported mammography reading achieved a lower interval-cancer rate than standard double reading (1.55 vs. 1.76 per 1,000, meeting noninferiority) with higher sensitivity (80.5%…
Primary source cited
Last reviewed
A single glioblastoma patient's response to neoadjuvant checkpoint immunotherapy has prompted a formal randomized Phase II trial (GIANT, at Duke University, testing nivolumab with or without relatlimab).
Primary source cited
Last reviewed
The study identifies GATA6 as an important regulator of colorectal-cancer biology and a potential research target, but it does not establish a GATA6-directed treatment for patients. Researchers found that knocking…
Primary source cited
Last reviewed
In the randomized, phase 3 AMBASSADOR trial, adjuvant pembrolizumab after radical surgery significantly extended disease-free survival compared with observation alone in patients with high-risk muscle-invasive or locally advanced urothelial carcinoma.…
Primary source cited
Last reviewed
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
Primary source cited
Last reviewed
In this prospective cohort, plasma KRAS ctDNA positivity correlated with worse survival and higher metastatic progression, while peritoneal KRAS ctDNA positivity correlated with occult/peritoneal metastatic risk — two related but…
Primary source cited
Last reviewed
Across two validation cohorts, an 18-gene urine test (MPS2) substantially outperformed PSA alone (AUC 0.81–0.82 vs. 0.60) for detecting higher-grade prostate cancer, with modeled reductions in unnecessary biopsies, including in…
Primary source cited
Last reviewed
In mismatch repair-deficient rectal cancer specifically, dostarlimab produced a high rate of clinical complete response — most of it sustained at 12 months, with 92% two-year recurrence-free survival across the…
Primary source cited
Last reviewed